vs
ExlService Holdings, Inc.（EXLS）与Indivior Pharmaceuticals, Inc.（INDV）财务数据对比。点击上方公司名可切换其他公司
ExlService Holdings, Inc.的季度营收约是Indivior Pharmaceuticals, Inc.的1.5倍（$542.6M vs $357.0M），Indivior Pharmaceuticals, Inc.净利率更高（28.9% vs 11.1%，领先17.7%），ExlService Holdings, Inc.自由现金流更多（$106.5M vs $-245.0M）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
EXLS vs INDV — 直观对比
营收规模更大
EXLS
是对方的1.5倍
$357.0M
净利率更高
INDV
高出17.7%
11.1%
自由现金流更多
EXLS
多$351.5M
$-245.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $357.0M |
| 净利润 | $60.2M | $103.0M |
| 毛利率 | 38.6% | 82.1% |
| 营业利润率 | 14.4% | 22.7% |
| 净利率 | 11.1% | 28.9% |
| 营收同比 | 12.7% | — |
| 净利润同比 | 18.9% | 390.5% |
| 每股收益（稀释后） | $0.38 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSINDV
| Q4 25 | $542.6M | $357.0M | ||
| Q3 25 | $529.6M | $314.0M | ||
| Q2 25 | $514.5M | $302.0M | ||
| Q1 25 | $501.0M | $266.0M | ||
| Q4 24 | $481.4M | — | ||
| Q3 24 | $472.1M | $307.0M | ||
| Q2 24 | $448.4M | $299.0M | ||
| Q1 24 | $436.5M | — |
净利润EXLSINDV
| Q4 25 | $60.2M | $103.0M | ||
| Q3 25 | $58.2M | $42.0M | ||
| Q2 25 | $66.1M | $18.0M | ||
| Q1 25 | $66.6M | $47.0M | ||
| Q4 24 | $50.7M | — | ||
| Q3 24 | $53.0M | $22.0M | ||
| Q2 24 | $45.8M | $-97.0M | ||
| Q1 24 | $48.8M | — |
毛利率EXLSINDV
| Q4 25 | 38.6% | 82.1% | ||
| Q3 25 | 38.5% | 73.2% | ||
| Q2 25 | 37.7% | 82.8% | ||
| Q1 25 | 38.6% | 83.1% | ||
| Q4 24 | 38.1% | — | ||
| Q3 24 | 37.8% | 78.5% | ||
| Q2 24 | 37.1% | 73.6% | ||
| Q1 24 | 37.4% | — |
营业利润率EXLSINDV
| Q4 25 | 14.4% | 22.7% | ||
| Q3 25 | 14.4% | 13.7% | ||
| Q2 25 | 15.8% | 23.8% | ||
| Q1 25 | 15.7% | 24.8% | ||
| Q4 24 | 14.8% | — | ||
| Q3 24 | 14.7% | 11.4% | ||
| Q2 24 | 13.7% | -39.5% | ||
| Q1 24 | 14.1% | — |
净利率EXLSINDV
| Q4 25 | 11.1% | 28.9% | ||
| Q3 25 | 11.0% | 13.4% | ||
| Q2 25 | 12.8% | 6.0% | ||
| Q1 25 | 13.3% | 17.7% | ||
| Q4 24 | 10.5% | — | ||
| Q3 24 | 11.2% | 7.2% | ||
| Q2 24 | 10.2% | -32.4% | ||
| Q1 24 | 11.2% | — |
每股收益（稀释后）EXLSINDV
| Q4 25 | $0.38 | $0.79 | ||
| Q3 25 | $0.36 | $0.33 | ||
| Q2 25 | $0.40 | $0.14 | ||
| Q1 25 | $0.40 | $0.38 | ||
| Q4 24 | $0.31 | — | ||
| Q3 24 | $0.33 | $0.16 | ||
| Q2 24 | $0.28 | $-0.72 | ||
| Q1 24 | $0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $195.0M |
| 总债务越低越好 | $298.6M | — |
| 股东权益账面价值 | $912.7M | $-98.0M |
| 总资产 | $1.7B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资EXLSINDV
| Q4 25 | $328.4M | $195.0M | ||
| Q3 25 | $390.1M | $445.0M | ||
| Q2 25 | $353.3M | $510.0M | ||
| Q1 25 | $331.4M | $373.0M | ||
| Q4 24 | $340.6M | — | ||
| Q3 24 | $325.8M | — | ||
| Q2 24 | $276.1M | — | ||
| Q1 24 | $246.2M | — |
总债务EXLSINDV
| Q4 25 | $298.6M | — | ||
| Q3 25 | $354.8M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $307.3M | — | ||
| Q4 24 | $288.5M | — | ||
| Q3 24 | $344.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EXLSINDV
| Q4 25 | $912.7M | $-98.0M | ||
| Q3 25 | $952.4M | $-207.0M | ||
| Q2 25 | $1.1B | $-257.0M | ||
| Q1 25 | $1.0B | $-285.0M | ||
| Q4 24 | $929.9M | — | ||
| Q3 24 | $907.6M | $-310.0M | ||
| Q2 24 | $852.6M | $-281.0M | ||
| Q1 24 | $803.3M | — |
总资产EXLSINDV
| Q4 25 | $1.7B | $1.2B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.7B | $1.4B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.4B | — |
负债/权益比EXLSINDV
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $-221.0M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | $-245.0M |
| 自由现金流率自由现金流/营收 | 19.6% | -68.6% |
| 资本支出强度资本支出/营收 | 2.0% | 6.7% |
| 现金转化率经营现金流/净利润 | 1.95× | -2.15× |
| 过去12个月自由现金流最近4个季度 | $298.1M | $-93.0M |
8季度趋势，按日历期对齐
经营现金流EXLSINDV
| Q4 25 | $117.4M | $-221.0M | ||
| Q3 25 | $120.7M | $-39.0M | ||
| Q2 25 | $109.4M | $158.0M | ||
| Q1 25 | $3.2M | $75.0M | ||
| Q4 24 | $105.3M | — | ||
| Q3 24 | $110.1M | $2.0M | ||
| Q2 24 | $74.9M | $88.0M | ||
| Q1 24 | $-21.9M | — |
自由现金流EXLSINDV
| Q4 25 | $106.5M | $-245.0M | ||
| Q3 25 | $106.4M | $-59.0M | ||
| Q2 25 | $95.0M | $141.0M | ||
| Q1 25 | $-9.7M | $70.0M | ||
| Q4 24 | $95.3M | — | ||
| Q3 24 | $97.3M | $-5.0M | ||
| Q2 24 | $62.8M | $84.0M | ||
| Q1 24 | $-33.1M | — |
自由现金流率EXLSINDV
| Q4 25 | 19.6% | -68.6% | ||
| Q3 25 | 20.1% | -18.8% | ||
| Q2 25 | 18.5% | 46.7% | ||
| Q1 25 | -1.9% | 26.3% | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.6% | -1.6% | ||
| Q2 24 | 14.0% | 28.1% | ||
| Q1 24 | -7.6% | — |
资本支出强度EXLSINDV
| Q4 25 | 2.0% | 6.7% | ||
| Q3 25 | 2.7% | 6.4% | ||
| Q2 25 | 2.8% | 5.6% | ||
| Q1 25 | 2.6% | 1.9% | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.7% | 2.3% | ||
| Q2 24 | 2.7% | 1.3% | ||
| Q1 24 | 2.6% | — |
现金转化率EXLSINDV
| Q4 25 | 1.95× | -2.15× | ||
| Q3 25 | 2.08× | -0.93× | ||
| Q2 25 | 1.66× | 8.78× | ||
| Q1 25 | 0.05× | 1.60× | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 2.08× | 0.09× | ||
| Q2 24 | 1.63× | — | ||
| Q1 24 | -0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
